Last reviewed · How we verify
NCT06638749
Effect of TXA on Blood Loss in Reverse Total Shoulder Arthroplasty
Phase 3 trial testing Tranexamic Acid in Shoulder Arthritis. Withdrawn.
1 December 2020
Quick facts
| Lead sponsor | University of Kansas Medical Center |
|---|---|
| Phase | Phase 3 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Start date | 1 May 2019 |
| Primary completion | 1 December 2020 |
| Estimated completion | 10 October 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Tranexamic Acid (Tranexamic Acid) — full drug profile →
- Normal Saline
Conditions studied
- Shoulder Arthritis — all drugs for Shoulder Arthritis →
- Blood Loss, Surgical — all drugs for Blood Loss, Surgical →
- Tranexamic Acid Adverse Reaction — all drugs for Tranexamic Acid Adverse Reaction →
Sponsor
University of Kansas Medical Center
Who can join
Eligibility, any sex, with Shoulder Arthritis or Blood Loss, Surgical. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Tranexamic acid (TXA) is a synthetic anti-fibrinolytic agent that has been well studied and routinely used for hip and knee arthroplasty. In hip and knee arthroplasty, the use of tranexamic acid decreases blood loss and the need for transfusion without increasing the risk of thromboembolic events. Due to the increased use of reverse total shoulder arthroplasty in the treatment of shoulder pathology, there has been interest in making the procedure safer for patients. TXA is a promising drug which could be useful to surgeons as they seek to achieve this goal, however, it has not been extensively studied in this setting. The purpose of this prospective randomized, controlled study is to determine the effectiveness and safety of using tranexamic acid to decrease blood loss in reverse total shoulder arthroplasty.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06638749
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Tranexamic Acid
Trials testing the same drug.
- NCT07501884 — REDUCER Trial (TXA in Urethroplasty) · Phase 4 · not yet recruiting
- NCT07460518 — Tranexamic Acid for Bleeding Reduction During TURP Surgery · Phase 4 · not yet recruiting
- NCT07390799 — Prophylactic Tranexamic Acid in Low-Risk Repeat Cesarean Delivery: A Randomized Controlled Trial · NA · not yet recruiting
- NCT07078942 — Prophylactic Intravenous Tranexamic Acid on Perioperative Blood Loss in Pregnant Women Undergoing Cesarean Section · Phase 4 · not yet recruiting
- NCT07263841 — Comparison of Effectiveness of Tranexamic Acid Mesotherapy Versus Glutathione Mesotherapy in Post Burn Facial Hyperpigme · Phase 2 · active not recruiting
Other recruiting trials for Shoulder Arthritis
Currently open trials in the same condition.
- NCT06319911 — AETOS Shoulder System · recruiting
- NCT04209504 — Evaluating Hemidiaphragmatic Paralysis With Prolonged Neural Blockade From an Interscalene Brachial Plexus Block · recruiting
- NCT04984291 — Zimmer Biomet Shoulder Arthroplasty PMCF · NA · recruiting
Other University of Kansas Medical Center trials
Trials by the same sponsor.
- NCT06636214 — Adapting Changing Talk: Online (CHATO) to CHATO-Inclusive · NA · not yet recruiting
- NCT07528963 — KanSurvive 2.0: Testing Enhanced Models of Cancer Survivorship Care for Rural Cancer Survivors in Primary Care Practice · NA · enrolling by invitation
- NCT07463755 — Low-Fidelity Driving Simulator Training in Parkinson's Disease. · NA · not yet recruiting
- NCT07420621 — Preliminary Effectiveness of Enhanced Text Message + Incentives · NA · recruiting
- NCT07491510 — Improving Prenatal Care to Reduce Early Onset Preeclampsia in Low-Income · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06638749 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Kansas Medical Center
- Last refreshed: 15 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06638749.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing